Lung Cancer EGFR: What Are The Latest Advanced Treatments in 2023? Insights from Ravi Salgia MD - Synopsis below extracted from the video transcript.
Dr. Ravi Salgia, a renowned thoracic oncologist, discusses the latest clinical trials in thoracic oncology that are expected to have a significant impact on cancer treatment in the coming years. Dr. Salgia begins by providing an overview of the current state of thoracic oncology, highlighting some of the challenges that researchers and clinicians face in treating lung cancer, mesothelioma, and other thoracic malignancies.
Dr. Salgia then dives into the latest clinical trials, including those focused on immunotherapy, targeted therapies, and combination therapies. He discusses the promising results seen in recent studies using immunotherapy drugs such as PD-1 inhibitors, CTLA-4 inhibitors, and CAR-T cell therapy. Dr. Salgia also talks about the potential of combining these therapies with chemotherapy, radiation therapy, or other targeted agents to further improve treatment outcomes.
Read The Full Transcript and Watch The Video Here
Additionally, Dr. Salgia highlights the latest research on targeted therapies, including drugs that target specific mutations such as EGFR, ALK, and ROS1. He discusses the various challenges associated with these targeted therapies, including drug resistance, and provides insights into ongoing research aimed at overcoming these obstacles.
Finally, Dr. Salgia provides an overview of the latest clinical trials in mesothelioma, a rare and aggressive form of cancer that affects the lining of the lungs, chest, or abdomen. He discusses the latest research on combination therapies, such as the use of immunotherapy and chemotherapy, and highlights the potential of novel treatments such as oncolytic viruses.
This video provides an insightful overview of the latest clinical trials in thoracic oncology, offering valuable insights for clinicians, researchers, and patients alike.
